ArticleActa ophthalmologica2026
The impact of systemic long-term medications for the development of age-related macular degeneration.
Article in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeAge-related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long-term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and immunosuppressants, is associated with the development of AMD.
methodsThe data included a pooled cohort of two follow-up studies: the Kuopio Osteoporosis Risk Factor and Prevention Study and the Kuopio Fall Prevention Study. A total of 16 518 women born between 1932 and 1946 living in eastern Finland were followed up between 1993 and 2021. The long-term medication use was indicated as ≥5 years of regular purchase of drugs. Incidence for AMD was analysed per long-term medication group, but also during the 5 years period in age matched groups.
resultsWe observed increased odds for AMD among long-term users of systemic corticosteroids (HR 1.348, p < 0.001), immunosuppressants (HR 1.623, p = 0.004) and antithrombotic (HR 1.145, p = 0.042) medication. However, results with antithrombotic medications were not as consistent as with corticosteroids and immunosuppressants. Interestingly, the mean age at diagnosis of AMD was later among antithrombotic medication users compared to the control group (77.9 vs. 76.1, respectively, p < 0.001) and earlier among patients using other diabetes medications than metformin (75.3 vs. 77.1, p = 0.026).
conclusionsPeople with long-term corticosteroid and immunosuppressant use are at greater risk for developing AMD. Further research on systemic components behind corticosteroid and immunosuppressant use, modulating AMD progression, is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.